Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom Evans

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
The Journal of Infectious Diseases|October 28, 2023
Reply to McShanePhilip C Hill, Frank Cobelens, Leonardo Martinez, et al.
Plos One|February 7, 2015
Structural and biochemical studies of a moderately thermophilic exonuclease I from Methylocaldum szegedienseLi Fei, SiSi Tian, Ruth Moysey, et al.
Science Advances|November 7, 2019
Degradation and forgone removals increase the carbon impact of intact forest loss by 626Sean L Maxwell, Tom Evans, James E M Watson, et al.
Vaccines|April 17, 2020
The Design and Development of a Multi-HBV Antigen Encoded in Chimpanzee Adenoviral and Modified Vaccinia Ankara Viral Vectors; A Novel Therapeutic Vaccine Strategy against HBVSenthil K Chinnakannan, Tamsin N Cargill, Timothy A Donnison, et al.
AIDS Research and Human Retroviruses|February 13, 2002
Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV diseaseAlan L Landay, Daniel Bettendorf, Ellen Chan, et al.
Plos Pathogens|February 12, 2014
Lectin-like bacteriocins from Pseudomonas spp. utilise D-rhamnose containing lipopolysaccharide as a cellular receptorLaura C McCaughey, Rhys Grinter, Inokentijs Josts, et al.
The Journal of Infectious Diseases|August 22, 2023
An Aspiration to Radically Shorten Phase 3 Tuberculosis Vaccine TrialsPhilip C Hill, Frank Cobelens, Leonardo Martinez, et al.
Scientific Reports|November 3, 2016
Adenovirally-Induced Polyfunctional T Cells Do Not Necessarily Recognize the Infected Target: Lessons from a Phase I Trial of the AERAS-402 VaccineMelissa Nyendak, Gwendolyn M Swarbrick, Amanda Duncan, et al.
NPJ Vaccines|September 14, 2018
The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trialRhea N Coler, Tracey A Day, Ruth Ellis, et al.
Cell Reports|May 3, 2018
STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis InfectionErik Van Dis, Kimberly M Sogi, Chris S Rae, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
The Journal of Infectious Diseases|October 28, 2023
Reply to McShanePhilip C Hill, Frank Cobelens, Leonardo Martinez, et al.
Plos One|February 7, 2015
Structural and biochemical studies of a moderately thermophilic exonuclease I from Methylocaldum szegedienseLi Fei, SiSi Tian, Ruth Moysey, et al.
Science Advances|November 7, 2019
Degradation and forgone removals increase the carbon impact of intact forest loss by 626Sean L Maxwell, Tom Evans, James E M Watson, et al.
Vaccines|April 17, 2020
The Design and Development of a Multi-HBV Antigen Encoded in Chimpanzee Adenoviral and Modified Vaccinia Ankara Viral Vectors; A Novel Therapeutic Vaccine Strategy against HBVSenthil K Chinnakannan, Tamsin N Cargill, Timothy A Donnison, et al.
AIDS Research and Human Retroviruses|February 13, 2002
Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV diseaseAlan L Landay, Daniel Bettendorf, Ellen Chan, et al.
Plos Pathogens|February 12, 2014
Lectin-like bacteriocins from Pseudomonas spp. utilise D-rhamnose containing lipopolysaccharide as a cellular receptorLaura C McCaughey, Rhys Grinter, Inokentijs Josts, et al.
The Journal of Infectious Diseases|August 22, 2023
An Aspiration to Radically Shorten Phase 3 Tuberculosis Vaccine TrialsPhilip C Hill, Frank Cobelens, Leonardo Martinez, et al.
Scientific Reports|November 3, 2016
Adenovirally-Induced Polyfunctional T Cells Do Not Necessarily Recognize the Infected Target: Lessons from a Phase I Trial of the AERAS-402 VaccineMelissa Nyendak, Gwendolyn M Swarbrick, Amanda Duncan, et al.
NPJ Vaccines|September 14, 2018
The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trialRhea N Coler, Tracey A Day, Ruth Ellis, et al.
Cell Reports|May 3, 2018
STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis InfectionErik Van Dis, Kimberly M Sogi, Chris S Rae, et al.
Pageof 6